Politiparty
Politiparty

118th Congress Health

H.R. 6227: Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023

Introduced

  1. Introduced (completed)Nov 3, 2023
  2. Passed House (not reached)
  3. Passed Senate (not reached)
  4. To the President (not reached)
  5. Became law (not reached)

Summary

Introduced in House, Nov 3, 2023

This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.

Written by the Congressional Research Service, Library of Congress.

Roll calls

0 votes on this bill

No roll call votes have been held on this bill.

Amendments

0 offered

No amendments were offered to this bill.

Cosponsors

35

Bipartisan support.

Who scored on this bill

12 points earned
  1. 1David Schweikert R-AZ SponsorDrew cross-party cosponsors, introduced, reached a cosponsor milestone3 events+12
See all scorers and every scoring event

Introductions and cosponsorships count toward weekly caps and show no points.

Other bills by David Schweikert

History

  1. Nov 3, 2023Introduced in the House by David Schweikert.
Show the full action history (3 actions)
  1. Nov 10, 2023Referred to the Subcommittee on Health.
  2. Nov 3, 2023Introduced in House
  3. Nov 3, 2023Referred to the House Committee on Energy and Commerce.